CENER|6 NAHE F0R 6EF0X|T|N |NJE6T|0N

6efox|t|n sod|um 1g, 2g; for |V |nj; sod|um content 2.3mEq|g.

LECAL 6LA88|F|6AT|0N:
Rx
PhARHA60L0C|6AL 6LA88 F0R 6EF0X|T|N |NJE6T|0N
6epha|ospor|n.
|N0|6AT|0N8 F0R 6EF0X|T|N |NJE6T|0N
3uscepl|o|e oacler|a| sepl|cer|a, |oWer resp|ralory or ur|rary lracl, s||r ard
s||r slruclure, oore ard jo|rl, gyreco|og|c, |rlraaodor|ra| |rlecl|ors.
3urg|ca| propry|ax|s.
A0ULT 008E F0R 6EF0X|T|N |NJE6T|0N
usua||y 1-2g every -8 rrs. urcorp||caled: 1g every -8 rrs. Voderale|y
severe lo severe: 1g every 1 rrs or 2g every -8 rrs. Vax 2g every 1 rrs or
3g every rrs. Propry|ax|s: see ||leralure.
6h|L0REN'8 008|NC F0R 6EF0X|T|N |NJE6T|0N
<3rorlrs: rol recorrerded. <3rorlrs: 80-10rg/|g per day |r 1- equa|
d|v|ded doses; rax 12g/day. Propry|ax|s: see ||leralure.
wARN|NC8|PRE6AUT|0N8 F0R 6EF0X|T|N |NJE6T|0N
Per|c||||r or olrer a||ergy. Rera| |rpa|rrerl (CrC| <50rL/r|r), reduce dose:
see ||leralure. 0l d|sease (esp. co||l|s). Pregrarcy (Cal.8). Nurs|rg rolrers.
|NTERA6T|0N8 F0R 6EF0X|T|N |NJE6T|0N
Ar|rog|ycos|des ray polerl|ale reprrolox|c|ly. Polerl|aled oy prooerec|d.
Vay cause la|se () C||r|lesl. Vay |rlerlere W|lr creal|r|re lesls.
A0VER8E REA6T|0N8 F0R 6EF0X|T|N |NJE6T|0N
Loca| reacl|ors, rasr, prur|lus, drug lever, 0l upsel, arapry|ax|s, o|ood
dyscras|as, e|evaled ||ver erzyres.
N0TE8 F0R 6EF0X|T|N |NJE6T|0N
Forrer|y |roWr urder lre orard rare Velox|r.
h0w |8 6EF0X|T|N |NJE6T|0N 8UPPL|E0?
Corlacl supp||er.
RELATE0 0|8EA8E:
lrlecl|ors, oacler|a|~sysler|c arl||rlecl|ves

AE: Nausea; vomiting; diarrhoea; hypersensitivity reactions;

nephrotoxicity; convulsions; CNS toxicity; hepatic dysfunction;
haematologic disorders; pain at nj site (M); thrombophloebitis
(V infusion); superinfection with prolonged use. Headache.
PotentiaIIy FataI: Pseudomembranous collitis.
MOA: Cefoxitin can induce -lactamase production by some
bacteria. t is resistant to a wide range of -lactamases,
including those produced byBacteroides spp.
NR:
Shake vigorously. Filter prior to administration via a 0.2
micron Pall filter.
2. oes not require further dilution.
3. Administer by slow !v injection over 3S minutes.
4. Compatible with NS, SW, 0W
S. o NOT mix with other drugs, !v solutions, blood or
blood products.
6. Flush line with NS before and after injection of
cefoxitin.
Nursing Considerations
. Assess site carefully for extravasation during injection
of cefoxitin.
2. Observe for signs of adverse effects.
3. Observe for signs of renal, hepatic or haematological
dysfunction during prolonged therapy.
4. Observe for signs of superinfection.
&torage
. At room temperature <2S C until reconstitution.
Protect from light.
2. !s not suitable for storage.
FANOT!!NE
Drug class: Histamine 2 (H
2
) antagonist

Therapeutic actions
Competitively blocks the action oI histamine at the
histamine (H
2
) receptors oI the parietal cells oI the
stomach; inhibits basal gastric acid secretion and
chemically induced gastric acid secretion.
Indications
O Short-term treatment and maintenance oI
duodenal ulcer
O Short-term treatment oI benign gastric
ulcer
O Treatment oI
pathologic hypersecretory conditions
O Short-term treatment
oI gastroesophageal reIlux disease (GERD),
esophagitis due to GERD
O RelieI oI symptoms oI heartburn, acid
indigestion, sour stomach (OTC)

ontraindications
O Allergy to Iamotidine; renal Iailure;
pregnancy; lactation.

dverse effects
Headache, malaise, di::iness, somnolence,
insomnia, Rash, Diarrhea, constipation, anorexia,
abdominal pain, Muscle cramp, increase in
totalbilirubin, sexual impotence

ursing considerations
O Administer drug at bedtime.
O Decrease doses with renal Iailure.
O Arrange Ior administration oI concurrent
antacid therapy to relieve pain.

:78ing Re85on8ibiIitie8:
1. Assess patient for abdominal pain
2. look for blood in emesis, stool
3. Tell the patient to take prescription drug with a snack, if
desired.
4. Urge patient to avoid cigarette smoking, it may increase
gastric acid secretion
5. advise patient to report abdominal pain.
6. Monitor VS prior to drug adiminstration.